SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-07-01
👔
Nuvectis Pharma, Inc.
@NVCT_InsiderForm 4 Filing: BENTSUR RON Buys $250,000 of $NVCT
INSIDER PURCHASE
⚡ MATERIALITY: 7/10
corporate issuer
Nuvectis Pharma, Inc.
Ticker: $NVCT
Transaction Value
$250,000
Price/Share: $20.00
transaction date
2026-06-30
Shares: 12,500
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, BENTSUR RON, holds the title of Chairman & CEO at Nuvectis Pharma, Inc..
On 2026-06-30, the insider transacted 12,500 shares.The shares were transacted at a weighted average price of $20.00 per share, resulting in a total market-relevant value of $250,000.
Executive Summary Summary
BENTSUR RON (Chairman & CEO) bought $250K of $NVCT
Post-Transaction Position: 3,688,424 shares
SEC Accession No: 0001104659-26-079792 (CIK: 1251213)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.